Shockwave Therapy for Erectile Dysfunction: Imaging Evidence

For over a decade, the case for low-intensity shockwave therapy in erectile dysfunction has rested almost entirely on what patients report: scores that rise after active treatment, sham groups that don't budge. What has been missing is a direct look at the tissue itself — until a 2024 sham-controlled trial pointed an ultrasound probe at the corpora cavernosa and watched the fibrosis recede after treatment.

Erectile dysfunction is most often vasculogenic in origin: the corpora cavernosa loses the elasticity needed to trap blood during an erection, a problem called corporal veno-occlusive dysfunction. Shockwave therapy for erectile dysfunction has been proposed as a way to reverse this fibrosis at the tissue level, and low-intensity extracorporeal shockwave therapy (LiESWT) is now among the field's more studied non-pharmacologic options. What follows below traces, what fails in that tissue, how LiESWT is thought to act on it, what a new imaging trial adds to the mechanism, and where the broader clinical evidence currently stands.

A 2024 sham-controlled trial found that active shockwave therapy for erectile dysfunction, but not sham treatment, produced a measurable reduction in cavernosal tissue fibrosis on ultrasound imaging. Blood-flow measures and total erectile-function scores improved as well. Whether that tissue-level change reliably translates into a clinically meaningful symptom improvement for every patient is the question the field is now working to answer.

What fails in erectile tissue? 

Erectile dysfunction is frequently vascular in origin, and in men with an organic cause the more common underlying problem is corporal veno-occlusive dysfunction: the smooth muscle and elastic tissue inside the corpora cavernosa are gradually replaced by fibrotic connective tissue. Healthy erectile tissue needs a specific balance of smooth muscle to connective tissue in order to expand fully and compress the veins that would otherwise let blood drain away. When fibrosis crowds out that smooth muscle, the veno-occlusive mechanism fails and the erection cannot be sustained. This is a structural problem rather than a purely neurological or hormonal one, which is part of why pharmacological approaches to blood flow do not resolve it for every patient — and why a treatment aimed at the tissue itself is of interest. On ultrasound, this fibrosis shows up as a hypoechoic (darker and less uniform) pattern in the corpora cavernosa, distinct from the more homogeneous appearance typically seen in men without erectile dysfunction.

How low-intensity shockwave reaches the tissue

Low-intensity shockwave therapy delivers focused pressure pulses through the skin into the erectile tissue, and the mechanical stress they create is converted into biochemical signals inside the cells — a process called mechanotransduction. In animal models, this mechanical stimulus increases the density of the body's own repair cells (mesenchymal stem cells) in the treated tissue, promotes release of vascular endothelial growth factor (VEGF), a signalling protein that drives new blood-vessel growth. Over time, these changes are thought to rebuild the smooth-muscle content of the corpora cavernosa and reduce the fibrosis described above. The cellular mechanism is well described in preclinical research, but confirming the same tissue-level changes in human erectile tissue has, until recently, relied on inference rather than direct observation.

The first human imaging of the tissue thange

Investigators at San Diego Sexual Medicine clinic used high-resolution grayscale ultrasound as a primary outcome — the first time tissue homogeneity had been visually graded before and after shockwave therapy for erectile dysfunction. Thirty-five men were randomized to active treatment on urogold100 or a true sham that delivered no energy.

Active treatment significantly reduced the fibrotic-appearing area on ultrasound and significantly lowered end-diastolic blood-flow velocity, a measure consistent with better venous compression. At baseline, greater tissue inhomogeneity on imaging correlated with worse erectile-function scores, which is what validates the imaging as a clinically relevant measure.

The tissue-level mechanism itself was already established in animal models; however, this trial adds the first non-invasive human corroboration of it.

---

Taken together, the tissue-imaging findings, the animal-model mechanism, and the pooled trial evidence describe a treatment that measurably changes fibrotic erectile tissue and improves function for many patients, while leaving open how reliably that translates into a clinically meaningful result for any one man in the chair. The 2024 imaging trial anchoring this tissue-level evidence was conducted on an electrohydraulic device, the urogold100.

MTS Medical's SparkWave systems are built on the same electrohydraulic, focused-shockwave physics that generated this tissue-imaging data, engineered to deliver energy within the therapeutic window the literature describes.

Visit MTS Science page for supporting evidence in the field of Sexual Health!

---

Disclaimer

This content is intended for qualified healthcare professionals only. It is for informational and educational purposes and does not constitute medical advice. Clinical decisions must be made by qualified healthcare professionals based on individual patient circumstances.